SG11202006148UA - Multi-domain immunomodulatory proteins and methods of use thereof - Google Patents
Multi-domain immunomodulatory proteins and methods of use thereofInfo
- Publication number
- SG11202006148UA SG11202006148UA SG11202006148UA SG11202006148UA SG11202006148UA SG 11202006148U A SG11202006148U A SG 11202006148UA SG 11202006148U A SG11202006148U A SG 11202006148UA SG 11202006148U A SG11202006148U A SG 11202006148UA SG 11202006148U A SG11202006148U A SG 11202006148UA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- immunomodulatory proteins
- domain immunomodulatory
- domain
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862613378P | 2018-01-03 | 2018-01-03 | |
US201862733622P | 2018-09-19 | 2018-09-19 | |
PCT/US2019/012222 WO2019136179A1 (en) | 2018-01-03 | 2019-01-03 | Multi-domain immunomodulatory proteins and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202006148UA true SG11202006148UA (en) | 2020-07-29 |
Family
ID=65409474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202006148UA SG11202006148UA (en) | 2018-01-03 | 2019-01-03 | Multi-domain immunomodulatory proteins and methods of use thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230101432A1 (de) |
EP (1) | EP3735417A1 (de) |
AU (1) | AU2019205273B2 (de) |
BR (1) | BR112020013236A2 (de) |
CA (1) | CA3087149A1 (de) |
SG (1) | SG11202006148UA (de) |
WO (1) | WO2019136179A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018512856A (ja) | 2015-04-17 | 2018-05-24 | アルパイン イミューン サイエンシズ インコーポレイテッド | 調整可能な親和性を有する免疫調節タンパク質 |
KR102536850B1 (ko) | 2016-04-15 | 2023-05-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
NZ746934A (en) | 2016-04-15 | 2023-11-24 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
AU2018235835A1 (en) | 2017-03-16 | 2019-09-05 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
CA3054068A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
CN111801347A (zh) | 2017-10-10 | 2020-10-20 | 高山免疫科学股份有限公司 | Ctla-4变体免疫调节蛋白和其用途 |
TW201925223A (zh) | 2017-10-18 | 2019-07-01 | 美商艾爾潘免疫科學有限公司 | 變異型icos 配位體免疫調節蛋白及相關組合物及方法 |
TW202208414A (zh) * | 2020-05-08 | 2022-03-01 | 美商艾爾潘免疫科學有限公司 | April及baff抑制性免疫調節蛋白及其使用方法 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (de) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Geänderte antikörper |
US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
US6218525B1 (en) * | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
AU674492B2 (en) | 1991-05-06 | 1997-01-02 | United States of America, as represented by the Department of Health and Human Services, The | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
JP4418965B2 (ja) | 1994-09-23 | 2010-02-24 | タップイミューン・インコーポレイテッド | 内在性ペプチドを有するmhcクラスi分子の発現を増強する方法 |
ATE197765T1 (de) | 1994-10-03 | 2000-12-15 | Us Gov Health & Human Serv | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック,インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP1068241B1 (de) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antikörper varianten und fragmente davon |
US20040063094A1 (en) | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
CA2336523C (en) | 1998-08-07 | 2015-06-30 | University Of Washington | Immunological herpes simplex virus antigens and methods for use thereof |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
AU2695101A (en) | 2000-01-21 | 2001-07-31 | Biovex Ltd | Virus strains |
CN1304559C (zh) | 2001-10-09 | 2007-03-14 | 杭州康科生物技术有限公司 | 表达热休克蛋白的溶瘤微生物及其应用 |
US7247615B2 (en) | 2001-11-30 | 2007-07-24 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Peptide agonists of prostate-specific antigen and uses therefor |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
JP4351674B2 (ja) | 2002-12-16 | 2009-10-28 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体とその使用法およびその使用 |
SI1718677T1 (sl) | 2003-12-19 | 2012-08-31 | Genentech Inc | Monovalentni protitelesni fragmenti, uporabni kot zdravila |
BR122019012028B1 (pt) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
JP2008505174A (ja) | 2004-07-15 | 2008-02-21 | ゼンコー・インコーポレイテッド | 最適化Fc変異体 |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
JP4958555B2 (ja) | 2004-09-22 | 2012-06-20 | 協和発酵キリン株式会社 | 安定化されたヒトIgG4抗体 |
US7550296B2 (en) | 2004-12-01 | 2009-06-23 | Bayer Schering Pharma Ag | Generation of replication competent viruses for therapeutic use |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
CA2621764A1 (en) | 2005-09-09 | 2007-03-15 | Zymogenetics, Inc. | Method for preparing trimeric proteins |
GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
KR101631323B1 (ko) | 2007-06-21 | 2016-06-17 | 엑스엘-프로테인 게엠베하 | 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질 |
US9796987B2 (en) | 2007-12-11 | 2017-10-24 | The University Of North Carolina At Chapel Hill | Polypurine tract modified retroviral vectors |
EP2398466B1 (de) | 2008-11-24 | 2021-02-17 | Massachusetts Institute of Technology | Verfahren und zusammensetzungen zur lokalisierten nanopartikel-abgabe an tumoren |
EP2283810A1 (de) | 2009-07-16 | 2011-02-16 | University College Cork-National University of Ireland, Cork | Oral verabreichte Bakterien als Träger zur systemischen Abgabe von Mitteln |
US20150359909A1 (en) | 2009-07-16 | 2015-12-17 | University College Cork-National University Of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
JP5972915B2 (ja) | 2011-03-16 | 2016-08-17 | アムジエン・インコーポレーテツド | Fc変異体 |
CN103596586A (zh) | 2011-04-08 | 2014-02-19 | 免疫设计公司 | 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法 |
WO2012149364A1 (en) | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
CA3179537A1 (en) | 2012-02-27 | 2013-09-06 | Amunix Pharmaceuticals, Inc. | Xten conjugate compositions and methods of making same |
CA2903546A1 (en) | 2013-03-15 | 2014-09-25 | Biogen Ma Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
WO2014198002A1 (en) | 2013-06-14 | 2014-12-18 | Ottawa Hospital Research Institute | A bacterium producing an interferon binding protein and uses thereof |
CA2931986A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
MX2017000630A (es) | 2014-07-15 | 2017-04-27 | Immune Design Corp | Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral. |
AU2015343048A1 (en) * | 2014-11-06 | 2017-05-18 | Children's Research Institute, Children's National Medical Center | Immunotherapeutics for cancer and autoimmune diseases |
EP3020816A1 (de) | 2014-11-11 | 2016-05-18 | University College Cork | Bakteriell vermittelte Gentherapie |
JP2018512856A (ja) | 2015-04-17 | 2018-05-24 | アルパイン イミューン サイエンシズ インコーポレイテッド | 調整可能な親和性を有する免疫調節タンパク質 |
CN108513576A (zh) * | 2015-09-14 | 2018-09-07 | 高山免疫科学股份有限公司 | 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗 |
NZ746934A (en) * | 2016-04-15 | 2023-11-24 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
KR102536850B1 (ko) | 2016-04-15 | 2023-05-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
-
2019
- 2019-01-03 AU AU2019205273A patent/AU2019205273B2/en active Active
- 2019-01-03 CA CA3087149A patent/CA3087149A1/en active Pending
- 2019-01-03 WO PCT/US2019/012222 patent/WO2019136179A1/en unknown
- 2019-01-03 US US16/959,662 patent/US20230101432A1/en active Pending
- 2019-01-03 EP EP19704899.4A patent/EP3735417A1/de active Pending
- 2019-01-03 SG SG11202006148UA patent/SG11202006148UA/en unknown
- 2019-01-03 BR BR112020013236-5A patent/BR112020013236A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019136179A1 (en) | 2019-07-11 |
CA3087149A1 (en) | 2019-07-11 |
EP3735417A1 (de) | 2020-11-11 |
US20230101432A1 (en) | 2023-03-30 |
BR112020013236A2 (pt) | 2020-12-01 |
AU2019205273B2 (en) | 2024-04-04 |
AU2019205273A1 (en) | 2020-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202006148UA (en) | Multi-domain immunomodulatory proteins and methods of use thereof | |
IL281783A (en) | SIRPa type binding proteins and methods of using them | |
IL276731A (en) | Antibodies against CD73 and methods of using them | |
IL273918A (en) | Trispecific proteins and methods of use | |
IL261666A (en) | Related proteins and methods of using them | |
IL281568A (en) | Collagen-local immunomodulatory molecules and their use | |
EP3635013A4 (de) | Nectin-4-bindende proteine und verfahren zur verwendung davon | |
SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
IL269074A (en) | Proteins that bind anti-TIGIT antigens and methods of using them | |
IL278821A (en) | Anti-SIRPA antibodies and methods of using them | |
IL280102A (en) | Fusion protein containing PD1-4-1BBL and methods of using it | |
ZA202003695B (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
IL270214A (en) | Anti-sortilin antibodies and methods of using them | |
IL279201A (en) | Multispecific binding proteins and methods of using them | |
IL289829A (en) | Antibodies for modulating the immune system and methods of using them | |
IL280103A (en) | Fusion protein containing SIRPalpha-4-1BBL and methods of using it | |
IL284157A (en) | Anti-pd-1 binding proteins and methods of using them | |
IL279648A (en) | Anti-SIRP-in-cell 1 antibodies and methods of using them | |
EP3891175A4 (de) | Modifizierte proteine und zugehörige behandlungsverfahren | |
IL283884A (en) | Antibodies against il-36 and methods of using them | |
IL280338A (en) | Anti-SIGLEC-5 antibodies and methods of using them | |
IL283830A (en) | A multigene structure for protein expression that modulates the immune system and methods of use | |
IL279227A (en) | Anti-SIGLEC-7 antibodies and methods of using them | |
IL284364A (en) | Anti-pd-l1 binding proteins and methods of using them | |
EP4025585A4 (de) | Modifizierte peptide und damit verbundene verwendungsverfahren |